Gonadotropin-releasing hormone agonist failure in a man with prostate cancer.
作者信息
Smith M R, McGovern F J
机构信息
Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
J Urol. 2001 Jul;166(1):211.
PMID:11435862
Abstract
摘要
相似文献
1
Gonadotropin-releasing hormone agonist failure in a man with prostate cancer.一名前列腺癌男性患者促性腺激素释放激素激动剂治疗失败
J Urol. 2001 Jul;166(1):211.
2
3
Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?促性腺激素释放激素激动剂在注射部位有无无菌性脓肿形成时的失效情况：对机制的深入了解？
Urology. 2006 May;67(5):1084.e15-7. doi: 10.1016/j.urology.2005.11.015.
4
Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?对于局限性前列腺癌患者，6个月的雄激素抑制疗法加放疗是否有益？
Nat Clin Pract Oncol. 2005 Jan;2(1):12-3. doi: 10.1038/ncponc0056.
5
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.局部晚期和转移性前列腺癌的间歇性雄激素抑制：一项前瞻性多中心研究的初步报告。
Urology. 2004 Aug;64(2):341-5. doi: 10.1016/j.urology.2004.03.032.
6
Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.垂体腺瘤继发促性腺激素释放激素类似物抗雄激素治疗失败
J Urol. 1998 Aug;160(2):497-8.
7
Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.在前列腺癌的初始激素治疗中，促黄体激素释放激素激动剂的不同给药方案会导致去势抵抗的早期发展有所不同。
Urology. 2011 Feb;77(2):412-6. doi: 10.1016/j.urology.2010.08.037. Epub 2010 Dec 15.
8
Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
J Chemother. 1989 Jul;1(4 Suppl):1237-41.
9
Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.一名前列腺癌患者在接受促性腺激素释放激素激动剂治疗后发现垂体腺瘤。
Int J Urol. 2006 Jan;13(1):87-8. doi: 10.1111/j.1442-2042.2006.01237.x.
10
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.新辅助激素治疗的前列腺癌患者骨髓中播散肿瘤细胞的预后意义
J Clin Oncol. 2008 Oct 20;26(30):4928-33. doi: 10.1200/JCO.2007.15.0441. Epub 2008 Sep 15.
引用本文的文献
1
Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.在接受黄体生成素释放激素激动剂治疗的前列腺癌患者中，未能达到去势水平的血清睾酮。
Anticancer Drugs. 2020 Nov;31(10):1099-1102. doi: 10.1097/CAD.0000000000000986.
Zotero 插件